Literature DB >> 9163674

In vitro activation of the human Harvey-ras proto-oncogene by aflatoxin B1.

J Riley1, H G Mandel, S Sinha, D J Judah, G E Neal.   

Abstract

Activation of ras proto-oncogenes occurs frequently in vivo in chemically induced rodent tumours, including rat hepatomas induced by aflatoxin B1. This study examines the in vitro activation of a human ras gene by this mycotoxin. A plasmid containing the human Ha-ras proto-oncogene, together with a neomycin resistance gene (pECneo), was incubated in vitro with a microsomal system generating aflatoxin B1 8,9-epoxide. Subsequent transfection of the plasmid into mouse NIH 3T3 fibroblasts, followed by G418 selection and s.c. injection of surviving cells into immunodeficient mice demonstrated that the proto-oncogene had acquired transforming capacity. Although a single tumour resulted from similar treatment of incubated unconjugated plasmid, no tumours were produced by a secondary round of transfections using DNA from this tumour. Selective PCR amplification of the human Ha-ras gene in extracted tumour DNA followed by sequencing demonstrated the presence of G-->T transversions either at the first or middle base of codon 12 in tumours resulting from transfection with the aflatoxin-B1-modified pECneo plasmid, but this was not detected in the single tumour resulting from transfection with the unmodified plasmid. Thus, although a mutation in the Ha-ras gene has not been reported for human primary hepatomas occurring in aflatoxin-exposed populations, metabolically activated aflatoxin B1 is capable of mutating this proto-oncogene to its oncogenic form in vitro. No mutations were observed in codon 61. It appears that, in contrast to the frequently reported G-->T transversions in codon 249 of the p53 gene in primary hepatomas in aflatoxin-exposed humans, the failure to detect Ha-ras mutations in these tumours is not due to an inability of aflatoxin B1 to activate this proto-oncogene. The G-->T transversions observed in this study contrast with the most frequent aflatoxin B1 in vivo induced mutations, G-->A transitions in the rat Ki-ras gene. Possible mechanisms for these differences are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163674     DOI: 10.1093/carcin/18.5.905

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Molecular basis of aflatoxin-induced mutagenesis-role of the aflatoxin B1-formamidopyrimidine adduct.

Authors:  Ying-Chih Lin; Liang Li; Alena V Makarova; Peter M Burgers; Michael P Stone; R Stephen Lloyd
Journal:  Carcinogenesis       Date:  2014-01-07       Impact factor: 4.944

2.  The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma.

Authors:  Maryann E Smela; Michelle L Hamm; Paul T Henderson; Constance M Harris; Thomas M Harris; John M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 3.  Aflatoxin B1 and M1: Biological Properties and Their Involvement in Cancer Development.

Authors:  Silvia Marchese; Andrea Polo; Andrea Ariano; Salvatore Velotto; Susan Costantini; Lorella Severino
Journal:  Toxins (Basel)       Date:  2018-05-24       Impact factor: 4.546

4.  Insights into Aflatoxin B1 Toxicity in Cattle: An In Vitro Whole-Transcriptomic Approach.

Authors:  Marianna Pauletto; Roberta Tolosi; Mery Giantin; Giorgia Guerra; Andrea Barbarossa; Anna Zaghini; Mauro Dacasto
Journal:  Toxins (Basel)       Date:  2020-06-29       Impact factor: 4.546

Review 5.  Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview.

Authors:  Christina Liava; Emmanouil Sinakos; Elissavet Papadopoulou; Lamprini Giannakopoulou; Stamatia Potsi; Anestis Moumtzouoglou; Anthi Chatziioannou; Loukas Stergioulas; Lydia Kalogeropoulou; Ioannis Dedes; Evangelos Akriviadis; Danai Chourmouzi
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

6.  Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea.

Authors:  Patrick Ying-Kit Yue; Yi-Yi Wong; Kay Yuen-Ki Wong; Yeuk-Ki Tsoi; Kelvin Sze-Yin Leung
Journal:  Chin Med       Date:  2013-11-01       Impact factor: 5.455

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.